Imunon Stock Soars 241.35% on Promising Cancer Treatment Data

On May 23, 2025, Imunon's stock surged by 241.35% in pre-market trading, marking a significant milestone for the clinical-stage biotechnology company.

Imunon, Inc. is dedicated to advancing a portfolio of treatments that leverage the body's natural mechanisms to combat a variety of human diseases. The company's innovative approach involves the development of non-viral DNA technology across four distinct modalities. TheraPlas is designed to code proteins and cytokines for the treatment of solid tumors, while PlaCCine focuses on coding viral antigens to elicit a strong immunological response. FixPlas aims to produce universal cancer vaccines, and IndiPlas is in the discovery phase, concentrating on personalized cancer vaccines.

The company's lead clinical program, IMNN-001, is a DNA-based immunotherapy specifically developed for the localized treatment of advanced ovarian cancer. This program has shown promising results, contributing to the recent surge in investor interest and stock performance. The prolonged survival observed in studies of IMNN-001 has further bolstered confidence in the company's innovative approach to cancer treatment.